What we're reading, July 28, 2016: CMS released first hospital quality ratings; Anthem is prepared to fight the government over Cigna purchase; and regulations are falling behind stem cell clinics.
Of the 3617 hospitals rated in CMS’ first hospital quality rating, just 102 received the top rating of 5 stars. According to Kaiser Health News, many of the nation’s best-known hospitals received average or below-average scores as part of the controversial rating system. Hospitals argue the ratings do not do enough to factor in the health of the patients being treated, which makes the hospitals that treat tougher cases look bad.
Anthem is prepared to fight the US Department of Justice (DOJ)’s efforts to block its acquisition of Cigna. Expecting to lose money on plans sold under the Affordable Care Act, Anthem is arguing that a merger with Cigna would let it negotiate better prices and pass savings on to consumers, reported Reuters. Last week, the DOJ sued to block Anthem’s acquisition of Cigna and Aetna’s purchase of Humana.
Although stem cell therapies are mostly theory at this point, new stem cell clinics are spreading as regulations fall behind. The New York Times blog The Upshot took a look at the world of stem cell clinics and how they are operating by working around the current laws in place. FDA does allow clinics to inject patients with their own stem cells, as long as cells meet certain criteria, but some of the treatments being advertised seem to flout FDA regulations.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More